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Abstract
Background: Hepatitis C virus (HCV) has six major genotypes, and patients infected with genotype 1 respond less well to
interferon-based therapy than other genotypes. African American patients respond to interferon a-based therapy at about
half the rate of Caucasian Americans. The effect of HCV’s genetic variation on treatment outcome in both racial groups is
poorly understood.
Methodology: We determined the near full-length pre-therapy consensus sequences from 94 patients infected with HCV
genotype 1a or 1b undergoing treatment with peginterferon a-2a and ribavirin through the Virahep-C study. The sequences
were stratified by genotype, race and treatment outcome to identify HCV genetic differences associated with treatment
efficacy.
Principal Findings: HCV sequences from patients who achieved sustained viral response were more diverse than sequences
from non-responders. These inter-patient diversity differences were found primarily in the NS5A gene in genotype 1a and in
core and NS2 in genotype 1b. These differences could not be explained by host selection pressures. Genotype 1b but not 1a
African American patients had viral genetic differences that correlated with treatment outcome.
Conclusions & Significance: Higher inter-patient viral genetic diversity correlated with successful treatment, implying that
there are HCV genotype 1 strains with intrinsic differences in sensitivity to therapy. Core, NS3 and NS5A have interferon-
suppressive activities detectable through in vitro assays, and hence these activities also appear to function in human
patients. Both preferential infection with relatively resistant HCV variants and host-specific factors appear to contribute to
the unusually poor response to therapy in African American patients.
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Introduction
Hepatitis C virus (HCV) causes acute and chronic hepatitis,
cirrhosis and hepatocellular carcinoma. Approximately 3.2 million
people in the United States are chronically infected with HCV [1].
About 20% of chronically HCV infected patients will develop liver
cirrhosis and approximately 10% of those patients will progress to
serious decompensated liver disease or hepatocellular carcinoma
[2]. HCV is the primary reason for liver transplantation and
causes 8000–12,000 deaths each year in the United States [1].
HCV is a single-stranded positive polarity RNA virus in the
Flaviviridae family (reviewed in [3]). It has an open reading frame of
,9600 nucleotides encoding a polypeptide of ,3000 amino acids,
which is proteolytically cleaved into 10 proteins (Figure 1). HCV is
highly diverse genetically, with six major genotypes differing from each
other by approximately 30–35% at the nucleotide level. Within each
genotype, there may be subtypes that vary by 20–25%, while within
each subtype, variation between isolates is typically 10–12% [4].
Treatment for HCV infection employs peginterferon a and
ribavirin for 24 to 48 weeks. 50–85% of patients achieve sustained
viral response (SVR; undetectable viremia six months post-
treatment) depending upon the HCV genotype [5]. Approximate-
ly 75% of infections in the United States are with genotype 1 [1]
and only 50–60% of patients infected with genotype 1 achieve
SVR. The reasons for this poor response are poorly understood
[5]. Among genotype 1 infected patients, African-American
patients (AA) clear the virus at only about half the rate of
Caucasian-Americans (CA) [6–8].
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The Virahep-C clinical study examined factors associated with
non-response to peginterferon a and ribavirin treatment in patients
infected with HCV genotype 1a or 1b and found that the poor
response to treatment in AA patients was not explained by clinical
factors associated with response such as gender, age, obesity, body
weight, severity of underlying hepatitis, pre-treatment viral levels, or
amount of drug taken [8]. As part of Virahep-C, we examined viral
genetic variation in 94 patients and found that higher inter-patient
HCV genetic diversity is closely associated with a robust response to
therapy at day 28 of treatment. This higher diversity was
predominately found in a few genes: NS3 and NS5A in genotype
1a, and core and NS3 in genotype 1b [9]. Importantly, these three
genes can counteract the effects of interferon a in cell-based assays
(reviewed in [10]). Because day 28 response is driven primarily by
response to peginterferon a, these data imply that core, NS3 and
NS5A variants with greater diversity are less able to block the effects
of interferon in vivo, rendering these viruses more susceptible to the
very strong interferon response induced by treatment. Our previous
analyses examined sequences from patients who had either very
poor or very good responses to therapy at day 28. Limiting this
analysis to the extremes of the response pattern and measuring the
response very early during treatment allowed us to focus on the
intrinsic biological effects of the drugs as much as possible.
However, the goal of therapy is eradication of the virus, not early
suppression of titres, and many biological and non-biological
variables can influence response to therapy between day 28 and the
six month post-treatment time point at which SVR is defined.
Therefore, we asked if there were viral diversity differences
associated with SVR, and if so, how they compared to the
associations with early response to treatment. To do this, we re-
analyzed the Virahep-C HCV sequences when they were stratified
by treatment outcome. We also divided the SVR and Non-
responder (NR) samples based on the patient race to evaluate
whether the HCV genetic associations with response to therapy
were similar in the two racial groups.
Results
Experimental Design and Patient Selection
The 94 Virahep-C patients that were analyzed in the Virahep-C
viral genetics study [9] were re-stratified by genotype (1a or 1b),
treatment outcome (SVR or NR) and race (CA or AA). Only the
pretreatment sequences were analyzed here; comparisons of the
pre- vs. post-treatment genotype 1a sequences are in [11]. The
breakdown of the sequences by treatment outcome, patient race
and day 28 response is in Table 1. There were similar numbers of
SVR and NR patients in the AA and CA groups because the viral
genetics cohort was evenly stratified by day 28 response. The
baseline clinical characteristics of the patients are in Table 2.
Use of the HCV Consensus Sequence
HCV replicates as a quasispecies, therefore, the virus can be
represented genetically either by characterizing the quasispecies
distribution or by using the consensus sequence of the quasispecies
to reflect the center of the genetic distribution in each individual.
We used the consensus sequence as determined by directly
sequencing HCV cDNA amplified from plasma [12] because this
study was designed to assess the role of inter-patient genetic
variation on outcome of treatment. We have compared the
consensus sequence with a near full-length quasispecies analysis in
the same patient and found that the consensus sequence was near
the center of the quasispecies distribution [13].
Inter-Patient HCV Genetic Diversity Is Associated with
SVR
An alignment and phylogenetic analysis of all SVR and NR
sequences revealed no clustering by response class (Figure 2), and
no single or limited number of amino acid variations were closely
associated with treatment outcome (data not shown). These results
have two implications. First, they indicate that the viruses from the
SVR and NR patients are not derived from separate evolutionary
lineages. Second, they reveal that response to interferon a-based
therapy is not strongly dependent upon simple amino acid
variations, such as are seen with antiviral therapies which target
the active site of a viral enzyme. These observations are consistent
with the pleoitropic cellular effects induced by interferon a, and
they imply that viral genetic signatures associated with response to
Figure 1. The HCV genome. The HCV genome contains a single major open reading frame flanked by untranslated regions. The 10 genes within
the open reading frame are indicated.
doi:10.1371/journal.pone.0009032.g001
Table 1. Cross-tabulation of the number of patients in
Virahep-C viral genetics cohort comparing the day 28
response classes and racial groups with treatment outcome.
Day 28 outcome
classes
Genotype Treatment
outcomea
Markedb Poorc Intermediated Total
1a SVR 15 2 5 22
NR 1 14 10 25
1b SVR 13 3 10 26
NR 2 13 6 21
Race of patiente
CA AA Total
1a SVR 11 11 22
NR 13 12 25
1b SVR 16 10 26
NR 7 14 21
aSVR, sustained viral response; NR, non-response.
bGreater than 3.5 log drop in viral titre or to undetectable between baseline and
day 28.
cLess than 1.4 log drop in viral titre between baseline and day 28.
dBetween 1.4 and 3.5 log drop in viral titre between baseline and day 28.
eCA, Caucasian American; AA, African American.
doi:10.1371/journal.pone.0009032.t001
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interferon-based antiviral therapy would be spread diffusely
through the viral genome. Therefore, we characterized the
HCV genetic diversity patterns in the pre-therapy genomes. This
analysis differed from our previous analysis [9] in that (i)
stratification was by treatment outcome (SVR vs NR) rather than
day 28 response, (ii) inclusion of the 30 day 28 intermediate
responders who were excluded from most of our previous analyses
to focus on the extremes of early response to treatment, and (iii)
performance of additional analyses to evaluate the association of
genetic variability with treatment outcome.
We first compared the number of variations in the SVR or NR
sequences relative to a genotype 1a or 1b population consensus
reference sequence. This reference sequence represents an
‘‘average’’ HCV sequence that is largely free from patient-specific
adaptations, such as those that can be driven by T-cell mediated
pressures [14]. Overall, the SVR sequences tended to be more
diverse, but these differences were not statistically significant
(Figures 3A and 3B). However, most HCV genetic variations are
anticipated to be neutral, so we eliminated the variations that were
common to both the SVR and NR sequences to focus on the
subset of variations which were most strongly associated with
response. The number of variations that was unique to the SVR
sequences was significantly higher than the number unique to NR
sequences for the entire polyprotein in both genotypes 1a and 1b
(p = 0.0010; Figures 3C and 3D). When the individual viral genes
were assessed, these differences were statistically significant at the
p#0.05 level for genotype 1a core, E1, NS3/4A and NS5A. For
genotype 1b, the differences were significant for core, E2, NS2,
NS3/4A and NS5A.
As a second measure of diversity, we analyzed the proportion of
unique variations relative to the total number of variations in the
SVR and NR sequences. For both genotypes 1a and 1b, there
were significantly more unique variations than expected in the
polyprotein of SVR patients and fewer unique than expected in
the NR sequences (p,0.001 for both, Table S1). For genotype 1a,
a significantly higher than expected proportion of unique
variations was observed for E1, E2, NS3/4A, NS5A and NS5B.
For genotype 1b, the core, E2, NS2, NS3/4A, NS4B and NS5A
proteins had significantly more unique variations than expected.
The previous measures of inter-patient HCV diversity can be
influenced by variations in the external reference sequence,
although our use of a population-wide consensus sequence
dampens this concern relative to using an arbitrary isolate as a
reference. Therefore, we assessed the genetic variation among the
HCV sequences by two additional measures that are not
dependent upon an external reference sequence, genetic distance
and Shannon’s entropy. Differences in the genetic distance among
the SVR and NR sequences were identified by determining the
genetic distance between each pair of sequences and then
comparing the average genetic distances between the two classes.
p7 was not analyzed by this method because it is so short that small
differences are magnified in the genetic distance calculations. In
both genotypes 1a and 1b, the average pairwise genetic distance of
the SVR polyprotein sequences was significantly larger than the
NR distance (Figures S1A and S1B). The genetic distances of the
NS3/4A and NS5A SVR sequences were significantly higher for
genotype 1a. The genotype 1b core, NS2 and NS3/4A genes from
the SVR sequences had significantly higher average genetic
distance compared to the NR sequences, with E2 approaching
significance (p = 0.052). Finally, Shannon’s entropy for each
position in alignments of SVR and NR sequences was assessed.
When the entire polyprotein was examined, the entropy of the
SVR samples was significantly higher than for the NR samples for
both genotypes (data not shown). For genotype 1a, core and NS5A
had significantly higher entropy for the SVR sequences compared
to NR sequences (Figure S2A). For genotype 1b, the entropy
values for core were significantly higher for SVR sequences (Figure
S2B).
In summary, the SVR polyprotein sequences were significantly
more diverse than the NR sequences by all four analytical methods
in both genotypes. For genotype 1a, NS5A was significantly more
diverse in the SVR samples by all four measures and core, E1 and
NS3/4A were more diverse by two of the measures. For genotype
1b, core was more diverse in the SVR samples by all measures,
and E2, NS2, NS3/4A and NS5A were more diverse in the SVR
samples by two or three of the four measures.
Effects of Host Responses on Viral Diversity
These diversity differences may be due to pre-existing viral
genetic differences that are causally associated with response.
Alternatively, patients who respond to therapy may have mounted
more effective T-cell responses, which could have driven greater
immune escape. This hypothesis is supported by the elevated
HCV-specific T-cell immune response among Virahep-C SVR
patients compared to NR patients [15]. To evaluate diversity
patterns in regions of the viral genome that were unlikely to be
under immune selection, we eliminated all known or predicted T-
cell epitope sequences [16] from this analysis regardless of their
restriction profile because the human lymphocyte antigen
identities were not available for these patients. We also eliminated
Table 2. Baseline characteristics of patients in the Virahep-C
viral genetics cohort.
Feature Statistic SVRa NRb
P
valuec
Number of patients N 48 46 –
AAd N (%) 21 (43.8%) 26 (56.5%) 0.2207
Male N (%) 31 (64.6%) 37 (80.4%) 0.0640
Genotype 1a N (%) 22 (45.8%) 25 (54.3%) 0.5606
Age (years) median
(25th, 75th)
46.5 (42.0, 50.0) 49.0 (45.0,53.0) 0.2777
Body weight (kg) median
(25th, 75th)
84.6 (72.0, 96.8) 89.6 (79.2,
101.7)
0.1022
HCV RNA
(log10IU/ml)
median
(25th, 75th)
6.0 (5.4, 6.8) 6.6 (6.4, 6.7) 0.0006
ALTe (U/L) median
(25th, 75th)
60.5 (44.0, 88.0) 69.5 (54.0,
102.0)
0.6145
Albumin (g/dl) median
(25th, 75th)
4.2 (4.0, 4.4) 4.2 (4.0, 4.4) 0.8317
Platelets
(61,000/mm)
median
(25th, 75th)
249.0 (197.5,
296.0)
205.5 (173.0,
250.0)
0.0006
AFPf (ng/ml) median
(25th, 75th)
4.1 (2.6, 5.6) 5.6 (3.7, 11.6) 0.7657
Ishak
necroinflamatory
score (0–18)
median
(25th, 75th)
7.0 (5.0, 9.0) 7.5 (6.0, 9.0) 0.1109
Ishak fibrosis score
(0–6)
median
(25th, 75th)
2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 0.2561
aSustained viral response.
bNon-response.
cUnivariate Poisson regression model.
dAfrican American.
eAlanine aminotransferase in serum.
fAlpha fetal protein in serum.
doi:10.1371/journal.pone.0009032.t002
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the E1 and E2 proteins because they are under humoral immune
selection. This approach eliminates far more sequence for each
HCV genome than is actually under immune selection in a given
patient, but its advantage is that the remaining sequences are very
unlikely to be under substantial immune selection. The mean
number of unique variations per sample outside T-cell epitopes was
compared between the response groups using a Poisson regression
analysis. For genotype 1a, diversity differences between the SVR
and NR sequences in non-epitope sequences were significant for
the polyprotein, core, NS3/4A, NS5A and NS5B (Figure 4A). For
genotype 1b, the diversity differences were significant for the
polyprotein, core, NS2, NS3/4A and NS5A when the epitope
sequences were excluded (Figure 4B). Therefore, immune selection
could not account for all diversity differences between the SVR
and NR sequences.
We next examined the observed/predicted ratio of UA and UU
dinucleotide frequencies in each sequence because these dinucle-
otides are substrates for RNaseL, a major effecter of the type 1
Figure 2. Phylogenetic tree for the genotype 1 polyprotein sequences. (A) A maximum-parsimony tree was generated from an alignment of
all 47 genotype 1a near full-length polyprotein sequences, with the genotype 1b consensus reference as the out-group. (B) A maximum-parsimony
tree was generated from an alignment of all 47 genotype 1b near full-length polyprotein sequences, with the genotype 1a consensus reference as
the out-group. Treatment outcome is indicated by SVR (boxed names) and NR (not boxed). AA patient sequences are shown in red; CA patient
sequences are in black.
doi:10.1371/journal.pone.0009032.g002
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interferon response. The observed/predicted UA and UU ratios
were less than 1.0 in all cases (Figure 5). For genotype 1a, the
observed/predicted UA ratio was higher in the SVR than NR
sequences (p = 0.013), but the UU ratio was the same in the SVR
and NR sequences. No significant differences either the UU or UA
ratios for genotype 1B were observed. This implies that all of the
sequences were under negative selective pressure from RNaseL,
but that the SVR and NR sequences were under similar levels of
pressure.
Recent work has identified eight cellular micro RNAs (miRNA)
which are induced by interferon b and have potential binding sites
in the HCV genome; some of these miRNAs have anti-viral
activity against HCV in cell culture [17]. The open reading frame
for each HCV genome in this study was examined for possible
miRNA targets for these eight miRNAs as well as miRNA-122, a
liver-specific miRNA the promotes HCV replication [18]. The
frequency of each match was determined for the SVR and NR
sequences as a group as well as for each sequence individually.
There were no significant differences in the frequencies of any
single miRNA seed match between SVR and NR sequences (data
not shown). The miRNAs were then grouped according to
whether they demonstrated anti-viral activity in culture or not. No
differences between NR and SVR were apparent in the frequency
with which the different groups of miRNA binding sites appear in
the genomes (Figure S3). In addition, the frequency of miRNA-
122 sites in the genomes also did not differ between the SVR and
NR sequences (data not shown). Therefore, if IFN-stimulated
miRNAs regulate HCV’s response to treatment, both response
classes appear to be equally susceptible to that regulation. Note
that this conclusion is limited to the HCV ORF because 39 or 59
UTR sequences were not available for all samples.
Prediction of Treatment Outcome Based on Amino Acid
Variations Unique to Day 28 Response
We previously reported that HCV sequences from day 28
marked responders are more variable than sequences from poor
responders [9]. All patients in the Virahep-C viral genetics cohort
had perfect drug compliance until day 28, therefore, HCV genetic
variations associated with day 28 response are related to the
intrinsic biological sensitivity of the virus in these patients to
therapy, without confounding issues that are present during the
demanding 24–48 week treatment regimen. We therefore assessed
whether pretreatment genetic variability associated with day 28
response could predict SVR. Table 3 shows the relative risks of
achieving SVR based on the number of variations unique to the
marked/poor day 28 response classes per genome. In both
Figure 3. Number of variations per sample by treatment outcome. The number of variations relative to a population consensus is shown for
the polyprotein (PP) and for each gene within the polyprotein. Statistical significance is shown for genes with p#0.05. (A) Genotype 1a, all variations.
(B) Genotype 1b, all variations. (C) Genotype 1a, variations unique to the SVR or NR classes. (D) Genotype 1b, variations unique to the SVR or NR
classes.
doi:10.1371/journal.pone.0009032.g003
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genotypes, higher numbers of marked/poor unique variations in
the polyprotein were associated with a significantly higher
probability of SVR. For each additional day 28 response-specific
unique variation, the probability of SVR was increased by 3% in
genotype 1a and 2% in genotype 1b. When each gene was
analyzed separately, core, E1, E2, NS3/4A, NS4B, NS5A and
NS5B were significant in genotype 1a, and core, E2, NS2 and
NS3/4A were significant for genotype 1b, with up to a 28%
increase in the probability of achieving SVR per additional unique
variation (genotype 1b core, Table 3).
Effect of Patient Race on Viral Diversity Associated with
SVR
The lower response of AA compared to CA patients in the
Virahep-C study could not be explained by disease characteristics,
baseline viral levels or amount of medication taken [8], and we
observed few significant effects of race on associations of inter-
patient HCV genetic diversity with day 28 outcome [9]. However,
day 28 response is primarily interferon-driven, whereas ribavirin
has a major impact on SVR rates [5,19]. Furthermore, the
antiviral mechanisms that suppress HCV titres may change after
day 28. Therefore, we asked whether the associations of viral
genetic diversity with SVR or NR differed between CA and AA
patients.
We first aligned the 1a and 1b sequences and generated a
neighbor-joining tree, using a different subtype consensus
reference as an out-group. There was no phylogenetic clustering
by race for either genotype 1a (Figure 2a) or genotype 1b
(Figure 2b). This indicates that the CA and AA patients are not
infected with substantially different HCV strains.
We next evaluated HCV genetic diversity differences in the CA
and AA patients by separating the data in Figure 3 by race of the
patient. For genotype 1a, there were significantly more unique
variations in the SVR group compared to the NR sequences for
the polyprotein, core, E1, p7, NS3/4A and NS5A in the CA
patients, whereas no significant differences were observed for AA
patients (Figure 6A). For 1b, the diversity differences between the
SVR and NR sequences in the polyprotein, core, E2, NS2 and
NS5A in the CA patients (Figure 6B). Within genotype 1b AA
patients, the diversity differences between the SVR and NR
sequences were also significant for the polyprotein, core and NS2
(Figure 6B).
Overall, splitting the data by race of the patient reduced the
statistical power of the analysis, but the diversity patterns observed
in the combined data sets were largely still apparent in the
genotype 1b CA and AA patients and the genotype 1a CA
patients. However, these patterns were essentially absent in the
Figure 4. Number of unique variations in non-epitope regions
by treatment outcome. Variations unique to the SVR or NR
sequences that were not in any known or predicted T-cell epitope
were compared in the SVR and NR samples. Statistical significance is
indicated where p#0.05. (A) Genotype 1a. (B) Genotype 1b.
doi:10.1371/journal.pone.0009032.g004
Figure 5. Ratio of observed to predicted UU and UA
dinucleotide frequencies. The ratios of observed to predicted
frequency of the dinucleotides UU and UA across the polyprotein were
compared between SVR and NR patients. Statistical significance is
indicated where p#0.05. (A) Genotype 1a. (B) Genotype 1b.
doi:10.1371/journal.pone.0009032.g005
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genotype 1a AA patients. This difference was most obvious when
the full polyprotein sequences were compared (Figure 6).
Discussion
The major HCV genotypes differ in their response to therapy
[5,19], but the effects of HCV genetic variation within a genotype
on treatment outcome are poorly understood. Here, we found pre-
treatment genetic variation was robustly associated with outcome
of treatment in the two major subtypes of genotype 1. Immune
selection could not account for all of the genetic association
(Figure 4), and we found no evidence for differential RNaseL
cleavage [20] (Figure 5) or differential regulation by cellular
miRNAs [17] (Figure S3) of the sequences in the SVR or NR
groups. Therefore, much of the difference in the pre-treatment
inter-patient viral genetic diversity appears to be causally
associated with treatment outcome.
The most consistent viral genetic associations with treatment
outcome were found in NS5A for genotype 1a and in core and
NS2 for genotype 1b. Our previous analysis comparing the day 28
marked and poor responders in a subset of the same cohort
revealed higher inter-patient diversity in the marked responders in
NS3 and NS5A for genotype 1a and in the core and NS3 for
genotype 1b [9]. Higher diversity was therefore associated with
worse response to the drugs for both day 28 response and
treatment outcome in the 1a NS5A and 1b core genes. The
association of higher diversity in NS2 with SVR for genotype 1b
but not with day 28 response may be due in part to increased
statistical power associated with the greater number of samples in
the treatment outcome analyses. The reduced strength of the
association of NS3 with treatment outcome compared to the day
28 response may be due to patient variables (such as drug
tolerance) influencing the outcome more over the longer time
period, and/or that the treatment outcome associations may be
influenced by both interferon a and ribavirin, whereas day 28
response is primarily influenced by interferon a.
The robust association of genetic diversity in core, NS3/4A and
NS5A with response to therapy strongly suggests that the
mechanisms by which genetic diversity affects treatment efficacy
are through altering the interferon-suppressive activities that have
been identified for these proteins in vitro [21–23]. The similarity of
the genetic associations with day 28 response and treatment
outcome suggests that the roles of these activities remain relatively
constant throughout the course of therapy. The distribution of
higher diversity associated with suppression of viral titers across
multiple viral proteins suggests that there are many ways lesions to
the HCV genome could reduce the efficacy of these suppressive
functions. HCV’s multi-pronged approach to controlling the type
1 interferon response may explain why not all of the SVR genomes
have elevated diversity in all genes with presumed interferon-
suppressive functions. In some cases having suboptimal function in
only one or two of the genes may have been sufficient to permit
interferon a-based therapy to drive the HCV to extinction.
A novel association of higher viral diversity in NS2 with SVR
was observed in genotype 1b. This association is difficult to
interpret because although the NS2 protease function has been
shown to be essential for assembly and production of infection
virus [24–26]; there is no evidence for a direct role in modulation
of the immune system. However, higher diversity in NS2 was also
associated with null response compared to relapse in the genotype
1a NR sequences [11], and therefore NS2 appears to play a role in
modulating the efficacy of antiviral therapy.
The genes in which high genetic diversity was associated with
SVR were not the same in genotype 1a and 1b. This implies that
HCV genotypes 1a and 1b do not rely on their common set of
interferon-suppressive functions in the same pattern. However, the
two genotypes respond to therapy at very similar rates [8], and
there are no reported differences in the frequency with which they
establish persistent infections. Therefore, although the mechanistic
details of how the two subtypes counteract the type 1 interferon
response appear to be somewhat different, the net efficacy of the
mechanisms they employ seems to be similar.
Viral sequence differences are clearly not the only determinant of
HCV’s response to therapy. This was recently demonstrated by four
groups who showed that single nucleotide polymorphisms (SNPs) in
the IL28B gene are closely associated with SVR [27–30]. Suppiah
et. al. [29] calculated that the population attributable risk for the
Table 3. Quantitative effect of each additional HCV genetic variation that is unique to the marked or poor day 28 response classes
on eventual treatment outcomea.
Genotype 1a Genotype 1b
Protein Relative Riskb (95% CIc) P valued Relative Riskb (95% CIc) P valued
Polyprotein 1.03 (1.02, 1.04) ,0.0001 1.02 (1.01, 1.04) 0.0019
Core 1.26 (1.11, 1.44) 0.0005 1.28 (1.14, 1.44) ,0.0001
E1 1.18 (1.07, 1.30) 0.0006 1.03 (0.88, 1.20) 0.7243
E2 1.10 (1.04, 1.17) 0.0012 1.08 (1.02, 1.15) 0.0102
p7 1.26 (0.87, 1.83) 0.2245 1.05 (0.74, 1.47) 0.7874
NS2 1.13 (0.99, 1.29) 0.0816 1.11 (1.04, 1.19) 0.0023
NS3+NS4A 1.14 (1.05, 1.25) 0.0029 1.08 (1.01, 1.16) 0.0232
NS4B 1.26 (1.01, 1.57) 0.0386 1.08 (0.92, 1.28) 0.3311
NS5A 1.06 (1.03, 1.10) 0.0005 1.03 (0.99, 1.07) 0.1127
NS5B 1.19 (1.08, 1.31) 0.0004 0.95 (0.82, 1.10) 0.4926
aComparing SVR (sustained viral response) vs. NR (non-response).
bFor example, a relative risk of 1.18 for E1 in genotype 1a indicates that for one additional marked/poor response-specific unique variation in this gene, the probability
of SVR is increased by 18%.
cCI, confidence interval.
dPoisson regression analysis.
doi:10.1371/journal.pone.0009032.t003
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favorable allele was 32%, indicating that variation within the IL28
locus is an important contributor to response, but is not the sole
determining factor. Furthermore, the favorable allele at this locus is
less frequent in African-Americans, partially explaining the poor
response to treatment in the AA population [27,30].
As an initial attempt to quantify the magnitude of the
contribution of viral diversity to outcome of therapy, we asked if
the number of variations unique to the early response categories
(marked or poor) could quantitatively predict SVR. The
probability of achieving SVR increased 2–3% with each additional
unique variation in the polyprotein (Table 3). These data imply
that a genotype 1a genome carrying 31 SVR-unique variations
(the mean number in genotype 1 SVR sequences) would have a
probability of response almost twice as high (31 variations X 3%/
variation = 93%) than a 1a virus carrying the population consensus
sequence that was used as a reference in this analysis. The effect
size is similar to that reported for variation in the IL28B gene [27].
The location of the variations was important, because the
quantitative effect of the number of variations was quite large
for some proteins. This was especially notable in core, where there
was a 26–28% increase in the probability of achieving SVR with
each additional unique variation (Table 3). The magnitude of
these quantitative effects was unexpectedly large given that the
only way we could reduce noise from neutral genetic differences
was to focus on variations unique to the SVR or NR groups.
The high proportion of AA patients enrolled in the Virahep-C
study allowed us to assess the effect of HCV’s genetic variation on
the unusually poor response of AA patients to therapy. In genotype
1b, the viral diversity patterns associated with treatment outcome
within the two racial groups were similar to the patterns observed
when the race was disregarded (compare Figures 3D and 6B). The
lower number of significant associations found when the racial
groups were analyzed separately appears to be primarily due to the
reduced statistical power from splitting the data set in half.
However, in genotype 1a infected patients, the overall pattern of
higher viral genetic diversity in the SVR patients that was present
in the full patient set was exaggerated in the CA sequences, but
diminished or absent in the AA sequences (compare Figures 3C
and 6A). Therefore, the genotype 1a AA sequences largely lack the
diversity patterns present in the 1a CA, 1b AA, and 1b CA
sequences. The lack of genetic associations with SVR in the 1a AA
patients implies that patient-specific factors may have been
dominant over viral-specific variables in these patients in
determining the outcome of therapy.
The SVR rate was 52% for CA and 28% for AA patients
among the 201 participants in Virahep-C [8]. However, our viral
Figure 6. Number of unique variations per sample by treatment outcome and patient race. The number of variations unique to either the
SVR or NR groups is shown for the polyprotein (PP) and for each HCV gene for CA and AA patients. Statistical significance is shown for genes with
p#0.05. (A) Genotype 1a. (B) Genotype 1b.
doi:10.1371/journal.pone.0009032.g006
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genetics cohort of 94 Virahep-C patients was selected to contain
equal numbers of day 28 responders and non-responders (the
‘‘marked’’ and ‘‘poor’’ groups) to adjust for response rate
differences. This led to an over-sampling of the SVR patients in
the AA group. The degree of over-sampling among the AA SVR
patients was 28% [(AA sequenced SVR)/AA total SVR)/(CA sequenced SVR/
CA total SVR) = 1.28]. The relative lack of viral genetic differences
between HCV strains infecting the CA and AA patients strongly
implies that the spectrum of viral strains circulating in the two racial
groups is similar. In this context, the 28% over-sampling of the SVR
patients in the AA population implies that although the viral strains in
the CA and AA patients are similar, the AA population is infected with
a higher proportion of relatively resistant viral strains. This preferential
circulation of HCV strains in the AA population is plausible because
AA patients are preferentially infected with genotype 1b compared to
CA patients [31]. The 28% over-sampling ratio in the AA SVR
patients therefore implies that one-quarter to one-third of the ,2-fold
difference in response rates for AA patients is due to preferential
infection of the AA population with HCV strains that are relatively
resistant to interferon a plus ribavirin therapy. This is consistent with
recent work by Ge et. al. [27] which found that genetic variation in the
IL28B gene was associated with the preferential clearance in CA
patients, but that other factors were also involved in the discrepancy in
treatment outcomes between CA and AA patients.
In sum, the presence of inter-patient HCV genetic variation
associated with treatment efficacy that cannot be attributed to
host selective pressures strongly implies that HCV genotype 1
sequences with varying sensitivity to interferon-based therapy
circulate in the population. This does not exclude prominent
roles for host factors in also affecting the outcome of therapy,
such as genetic variation in the IL28B gene. However, the
existence of viral genetic variations that are robustly associated
with outcome of therapy raises the possibility that identification
of key viral sequence motifs may help predict the outcome of
therapy. The failures of predictive algorithms based on analysis
of small regions of the genome such as the ‘‘interferon
sensitivity determining region’’ [32], our own failure to find
simple genetic lesions that sensitize the virus to therapy, and the
distribution of diversity differences associated with treatment
outcome across many viral genes indicate that identification of
these viral motifs will require approaches that evaluate multiple
viral genetic features. Furthermore, the different genetic
associations with SVR in genotypes 1a and 1b indicate that
such prognostic tests will need to be genotype-specific. Using
this Virahep-C cohort we recently identified genome-wide
amino acid covariance networks that were strikingly different in
SVR and NR patients [33]. These networks (or other genome-
wide analytical approaches) may be especially useful in
identifying highly-resistant viral strains that would be non-
responsive to interferon-based therapy. Infection with such
strains would be a contraindication for therapy, eliminating the
painful side-effects experienced by these patients during failed
therapy while generating large financial savings in the health
care system.
Materials and Methods
Virahep-C
Virahep-C was a study of peginterferon a and ribavirin therapy
in treatment-naı¨ve participants chronically infected with HCV
genotype 1 [8]. Virahep-C enrolled 205 CA and 196 AA
participants, all of whom were treated with peginterferon a-2a
(PegasysTM, Roche Pharmaceuticals; 180 mg weekly by subcuta-
neous injection) and ribavirin (CopegusTM, Roche Pharmaceuti-
cals; 1000 mg/day for those who weighed ,75 kg or 1200 mg/
day for those who weighed $75 kg, orally). Treatment was for up
to 48 weeks; therapy was discontinued for patients with detectable
viremia at 24 weeks. Serum HCV RNA levels were quantified as
described [8], and the primary outcome was SVR. All patients
gave written informed consent to the Virahep-C study and its
integral basic science studies, and this project was approved by the
Saint Louis University Institutional Review Board.
Sequencing
Consensus sequences for the full HCV ORF from pre-therapy
samples (Genbank EF407411 to EF407504) were obtained by
directly sequencing overlapping RT-PCR amplicons as described
[12].
Sequence Analyses
The genotype 1a and 1b samples were analyzed separately
because sequence variation between the genotypes was anticipated
to be larger than differences associated with response to therapy.
All analyses except UU/UA frequency analyses and miRNA seed
matches were conducted at the amino acid level. Sequence
alignments were done with ClustalW. Positions that varied relative
to the genotype 1a or 1b population consensus sequence were
identified with Mutation Master [34]. The genotype 1a consensus
reference sequence was derived from all 12 full-length ORFs in the
Los Alamos [35] and European [36] HCV databases in April,
2005, plus five 1a ORFs we sequenced from non-Virahep-C
cohorts. The genotype 1b population consensus reference
sequence was generated from all 126 full-length ORFs from
different patients in the databases in January, 2006. The known
and predicted CD4+ and CD8+ T-cell epitope sequences were
obtained from the HCV Immunology Database in July 2007 [16].
Shannon’s entropy [37] was calculated with Bioedit [38]. The
mean genetic distance was calculated using the p-distance
algorithm in the MEGA v. 4 DNA analysis package [39].
miRNA Seed Sequence Searches
The HCV sequences were searched for complimentarity to the
seed sequences using Patmatch [40]. The seed sequences of each
of the miRNAs were defined based on criteria described in [41].
Statistical Analyses
Fisher’s exact test was used to compare the proportions of
unique variations between the response groups. Shannon’s entropy
values were compared using the Mann-Whitney rank-sums test,
and the average genetic distances between the groups were
compared using an independent samples t-test. The association of
viral diversity and SVR was assessed through a Poisson (log-linear)
regression model with a Bonferroni post-hoc correction. The
number of unique variations between SVR and NR when split by
race was compared using the Mann-Whitney rank-sums test. The
level of significance (a) was set at 0.05 and statistical analyses were
done using SAS software (SAS Institute, Inc.) or SPSS v. 13.0
(SPSS, Inc.).
Supporting Information
Table S1 Comparison of the proportion of unique variations in
the SVR and NR sequences.
Found at: doi:10.1371/journal.pone.0009032.s001 (0.10 MB
DOC)
Figure S1 Average genetic distance by treatment outcome. An
alignment was created for the polyprotein and each individual
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protein (except p7). The p-distance was calculated for each pair in
the alignment. The average genetic distance of the SVR sequences
was compared to the NR sequences. The significance of the
difference between the groups was determined using an indepen-
dent samples t-test and is indicated for those genes where
p#,0.05. (A) Genotype 1a. (B) Genotype 1b.
Found at: doi:10.1371/journal.pone.0009032.s002 (6.05 MB TIF)
Figure S2 Shannon’s entropy of aligned sequences treatment
outcome. An alignment was created for the polyproteins of each
genotype. The entropy of each position in the alignment was
calculated. The rank sum of the entropy for the SVR sequences
was compared to the NR sequences for each protein. The
significance of the difference between the groups was determined
using an Mann-Whitney rank sums test and is indicated for those
genes where p#,0.05. (A) Genotype 1a. (B) Genotype 1b.
Found at: doi:10.1371/journal.pone.0009032.s003 (5.57 MB TIF)
Figure S3 Frequency of miRNA seed matches to the HCV open
reading frame between treatment outcome. The number of perfect
matches for each class of miRNA was compared between SVR
and NR sequences. The classes of miRNA were based on [17].
Those srepresented by the blue box are induced by interferonb but
have no apprent anti-viral activity in culture. The miRNAs
represented by the green boxes are induced by interferonb and
have anti-viral activity towards HCV in culture. The miRNAs
represented by the purple box are not induced by interferonb.
miR-122 is a liver specific RNA that is required for HCV infection
[18]. (A) Genotype 1a. (B) Genotype 1b.
Found at: doi:10.1371/journal.pone.0009032.s004 (7.13 MB TIF)
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